Figure 5.

B-Cell Therapies That Target B-Cell Survival Inhibit Interaction of APRIL and BAFF With TACI, BCMA, and BAFFR on B Cells

Binding of APRIL and BAFF ligands activates an intracellular signaling cascade via NF-κB that results in transcription of genes that enhance B cell survival. Atacicept inhibits binding of APRIL on BCMA and TACI and binding of BAFF on BAFFR, while belimumab, blisibimod and ianalumab target only binding between BAFF and BAFFR. APRIL = A proliferation-inducing ligand; BAFF = B-cell activating factor; BAFFR = B-cell activating factor receptor; BCMA = B-cell maturation antigen; BCR = B cell receptor; TACI = transmembrane activator and CAML interactor; other abbreviations as in Figure 2.